Functional Status Predicts Death After Lung TransplantFunctional Status Predicts Death After Lung Transplant

The risk for mortality is much lower for lung transplant patients discharged from the medical intensive care unit with a better functional status. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Related Links:

Voriconazole exposure and longer duration of voriconazole were found to be significantly associated with increased risk of squamous cell carcinoma. Regular dermatologic surveillance should be considered for the patients taking voriconazole, especially those at high risk of developing squamous cell carcinoma.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Source Type: research
Condition:   Respiratory Insufficiency Intervention:   Other: Questionnaire BPI Sponsor:   Assistance Publique Hopitaux De Marseille Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Transplant-Related Disorder;   Frail Elderly Syndrome;   Sarcopenia;   Lung Graft Dysfunction;   Mobility Limitation Intervention:   Other: Ambulation Sponsor:   The Cleveland Clinic Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The diagnostic criteria for antibody-mediated rejection (AMR) after lung transplantation (LTx) includes immunohistochemistry (IHC) staining patterns for C4d but not C3d.1 Historically, C3d deposition is a recognized complication after LTx associated with primary graft dysfunction and early bronchiolitis obliterans syndrome (BOS)2,3 but is not widely used in LTx even though it's a result of complement deposition via the classical pathway.4 The International Society for Heart and Lung Transplantation Pathology Council established a threshold of>50% deposition of C4d in interstitial capillaries as diagnostic but emphasized...
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Case Anecdotes, Comments and Opinions Source Type: research
Lung donor utilization rates remain low with many organs refused for donor quality. However, certain centers have successfully transplanted these organs despite multiple refusals for donor quality (RDQ) by other centers. We hypothesize that the number of refusals due to donor quality does not impact post-transplant outcomes.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
Significant right ventricular failure accompanying left ventricular failure was treated by implantation of the fully magnetically levitated centrifugal HeartMate 3 ventricular assist device as bi-ventricular support in 14 patients in 6 medical centers worldwide. The clinical details of this first multi-center experience are described, with 9 of these patients (64%) being alive as of January 1, 2018 - 8 of them ongoing on BiVAD support for 95 - 636 (mean 266) days, 7 of them at home, and one successfully transplanted after 98 days of support.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Innovation Source Type: research
Hepatitis C (HCV) donors are rarely used for cardiac transplantation due to historically poor outcomes. In 2015, nucleic acid testing (NAT) for viral load was added to the routine work-up of organ donors, allowing for the distinction between subjects who remain viremic (HCV Ab+/NAT+) and those who have cleared HCV and are no longer viremic (HCV Ab+/NAT –). The American Society of Transplantation recently recommended that HCV Ab+/NAT– donors be considered non-infectious and safe for transplantation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: ORIGINAL CLINICAL SCIENCE Source Type: research
Conclusions: In patients with FIP, PVR is a significant contributor of 6MWD, independently from the extent of fibrosis on HRCT. These results strengthen both the rationale to use 6MWD as endpoint in FIP and to target APH with specific therapies.Respiration
Source: Respiration - Category: Respiratory Medicine Source Type: research
Conditions:   Transplant-Related Disorder;   Frail Elderly Syndrome;   Sarcopenia;   Lung Graft Dysfunction;   Mobility Limitation Intervention:   Other: Ambulation Sponsor:   The Cleveland Clinic Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Health | Intensive Care | Lung Transplant | Transplant Surgery | Transplants